At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 45 enrolled
Drug / intervention
Pembrolizumab +1 moredrug
Likely dose
Pembrolizumab 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pembrolizumab (MK-3475) and Epacadostat (INCB024360) in Thymic Carcinomas
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab and Epacadostat for Thymic Carcinoma and 2 related conditions. Targeting 45 participants across 1 site.
Detailed Summary
This is a non-randomized clinical trial in patients with thymic carcinomas who failed prior systemic therapy. All subjects will receive pembrolizumab and epacadostat treatment in three week cycles until unacceptable toxicity, death, progressive disease or withdrawal.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThymic Carcinoma, Thymus Neoplasms, Thymus Cancer
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC, Incyte Corporation
Timeline
Phase 2UnknownOverdue
201520162017201820192020202120222023202420252026
First PostedFeb 2015
Enrollment StartMar 2015
Primary CompletionJun 2019
Study CompletionDec 2021
TodayJul 2026
First PostedFeb 16, 2015
Enrollment StartMar 1, 2015
Primary CompletionJun 1, 2019
Study CompletionDec 1, 2021
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 11.4 years ago
Interventions
Pembrolizumabdrug
Administration of 200 mg MK-3475 once every 3 weeks
Epacadostatdrug
100mg taken by mouth twice daily